Startup · $53m raised
Every investor coverage indicates participated in a round George Health raised.
| Investor | Rounds | Invested |
|---|---|---|
| Federation | Unnamed stage | - |
| Bupa | Unnamed stage | - |
Every published round George Health took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| George Medicines | Unnamed stage | 10 Mar 2020 | $20m | Participant | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Companies George Health has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| George Medicines | 10 Mar 2020 | 1 | 0 |
Fund closes reported for George Health, as distinct from the investments it has made.
Companies George Health has backed that another company then bought. An exit for the holding, not a deal George Health did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| No portfolio company of George Health is recorded as having been acquired. | ||||
Companies George Health acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Staph Leavenworth Bakali | Chief Executive Officer and President | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Stories naming George Health. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
George Medicines, a George Institute spin-out developing combination blood pressure therapies, has appointed former CSL Behring chief medical officer Dr Charmaine Gittleson as an independent non-executive director as its drug GMRx2 enters Phase III trials.
Drug developer George Medicines has added Dr Charmaine Gittleson to its board as an independent non-executive director, bringing pharma and CSL Behring leadership experience as its hypertension candidate GMRx2 advances through Phase III trials.
George Medicines has begun two Phase III trials testing its triple-combination pill GMRx2 as a first-line hypertension treatment, with patient availability possible by 2023 pending US regulatory approval.
Drug developer George Medicines has started two Phase III trials of its GMRx2 triple-combination pill as a first-line hypertension therapy, enrolling patients across seven countries, with possible availability by 2023 pending US regulator approval.
Drug developer George Medicines has named Stefan König, previously a senior Takeda executive, as its chief executive, while chief business officer Karl Roberts moves into the chief operating officer role.
George Medicines has named Stefan König, previously a Takeda franchise head, as its new CEO, while Karl Roberts moves from Chief Business Officer to Chief Operating Officer. The company also announced US FDA clearance to begin Phase III trials of GMRx2.
The George Institute's commercial arm and its drug development company have secured $53 million from three Australian investors to speed commercialisation of medical research, with Brandon Capital's Ingmar Wahlqvist involved.
Federation Asset Management announces an investment in George Health Enterprises, part of a 53 million dollar cash injection from Australian investors, described as a major private-public health partnership.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio